IL155282A0 - Vaccines - Google Patents

Vaccines

Info

Publication number
IL155282A0
IL155282A0 IL15528201A IL15528201A IL155282A0 IL 155282 A0 IL155282 A0 IL 155282A0 IL 15528201 A IL15528201 A IL 15528201A IL 15528201 A IL15528201 A IL 15528201A IL 155282 A0 IL155282 A0 IL 155282A0
Authority
IL
Israel
Prior art keywords
vaccines
Prior art date
Application number
IL15528201A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/690,921 external-priority patent/US6544518B1/en
Priority claimed from GB0025573A external-priority patent/GB0025573D0/en
Priority claimed from GB0025574A external-priority patent/GB0025574D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL155282A0 publication Critical patent/IL155282A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15528201A 2000-10-18 2001-10-16 Vaccines IL155282A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/690,921 US6544518B1 (en) 1999-04-19 2000-10-18 Vaccines
GB0025573A GB0025573D0 (en) 2000-10-18 2000-10-18 Vaccine
GB0025574A GB0025574D0 (en) 2000-10-18 2000-10-18 Vaccine
PCT/EP2001/011984 WO2002032450A2 (en) 2000-10-18 2001-10-16 Vaccines

Publications (1)

Publication Number Publication Date
IL155282A0 true IL155282A0 (en) 2003-11-23

Family

ID=27255945

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15528201A IL155282A0 (en) 2000-10-18 2001-10-16 Vaccines

Country Status (18)

Country Link
EP (2) EP1889630B1 (cs)
JP (1) JP2004511527A (cs)
KR (1) KR100860893B1 (cs)
CN (1) CN100548373C (cs)
AU (2) AU2002244337B2 (cs)
BR (1) BR0114786A (cs)
CA (1) CA2425358C (cs)
CZ (1) CZ302449B6 (cs)
DK (1) DK1326638T3 (cs)
ES (1) ES2295229T3 (cs)
HU (1) HU229642B1 (cs)
IL (1) IL155282A0 (cs)
MX (1) MXPA03003408A (cs)
NO (1) NO335919B1 (cs)
NZ (1) NZ525320A (cs)
PL (1) PL208755B1 (cs)
SI (1) SI1326638T1 (cs)
WO (1) WO2002032450A2 (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
WO2003055514A1 (en) 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
NZ537002A (en) * 2002-06-20 2006-06-30 Cytos Biotechnology Ag VLPs bound to immunostimulatory substances for use as adjuvants mixed with an antigen for enhancing immune response
WO2004019979A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccine comprising il-13 and an adjuvant
EA008741B1 (ru) 2003-10-30 2007-08-31 Коли Фармасьютикал Гмбх Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
EP1781325A2 (en) * 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1812052A1 (en) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310336B2 (en) 2005-11-04 2011-02-03 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
KR20130108983A (ko) 2010-05-26 2013-10-07 셀렉타 바이오사이언시즈, 인크. 커플링되지 않은 애주번트를 갖는 나노담체 조성물
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
US20130039954A1 (en) 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
US20140206574A1 (en) * 2011-08-31 2014-07-24 Karen Chapman Methods and Compositons for the Treatment and Diagnosis of Cancer
HUE039215T2 (hu) 2012-05-16 2018-12-28 Immune Design Corp Vakcinák HSV-2-höz
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
CA2879066C (en) * 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
SG10201704611WA (en) * 2012-12-13 2017-07-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
LT2996473T (lt) 2013-05-18 2019-12-10 Aduro Biotech Inc Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR101943171B1 (ko) * 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
JP7779839B2 (ja) 2019-12-13 2025-12-03 遠大賽威信生命科学（南京）有限公司 医薬組成物及びその用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69929310T2 (de) * 1998-02-05 2006-08-03 Glaxosmithkline Biologicals S.A. Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
BR9910643A (pt) * 1998-05-22 2001-10-30 Loeb Health Res Inst At The Ot Processos e produtos para a indução de imunidadede mucosa
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
TR200102191T2 (tr) * 1999-01-29 2001-12-21 Corixa Corporation HER-2/neu füzyon proteinleri.
CZ303515B6 (cs) * 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
CA2397374A1 (en) * 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.

Also Published As

Publication number Publication date
EP1326638B9 (en) 2008-02-20
HUP0402067A2 (hu) 2005-01-28
CZ20031093A3 (cs) 2003-08-13
CN1481255A (zh) 2004-03-10
EP1326638A2 (en) 2003-07-16
ES2295229T3 (es) 2008-04-16
CZ302449B6 (cs) 2011-05-25
MXPA03003408A (es) 2005-06-30
KR100860893B1 (ko) 2008-09-29
PL208755B1 (pl) 2011-06-30
EP1889630B1 (en) 2011-11-23
CN100548373C (zh) 2009-10-14
JP2004511527A (ja) 2004-04-15
NO335919B1 (no) 2015-03-23
WO2002032450A3 (en) 2002-10-10
AU4433702A (en) 2002-04-29
AU2002244337B2 (en) 2005-08-11
WO2002032450A2 (en) 2002-04-25
CA2425358C (en) 2012-08-21
PL365598A1 (en) 2005-01-10
NO20031705D0 (no) 2003-04-11
DK1326638T3 (da) 2008-03-25
HUP0402067A3 (en) 2012-09-28
EP1326638B1 (en) 2007-11-28
KR20070114230A (ko) 2007-11-29
EP1889630A1 (en) 2008-02-20
BR0114786A (pt) 2003-08-12
NZ525320A (en) 2004-10-29
SI1326638T1 (sl) 2008-04-30
HU229642B1 (en) 2014-03-28
NO20031705L (no) 2003-06-14
CA2425358A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
HUP0402067A3 (en) Vaccines
GB0020953D0 (en) Vaccine
HUP0301092A3 (en) Vaccine
IL155072A0 (en) Vaccine
HUP0202885A3 (en) Vaccines
AU1591402A (en) Vaccine
HUP0402259A3 (en) Vaccines
GB0024200D0 (en) Component vaccine
GB0014288D0 (en) Vaccine
GB9901254D0 (en) Vaccines
GB0014845D0 (en) Vaccine
GB0026334D0 (en) Vaccine
GB0025694D0 (en) Vaccine
GB0105238D0 (en) Vaccines
GB0003082D0 (en) Vaccine
GB0004533D0 (en) Vaccines
GB0006693D0 (en) Vaccine
GB0015722D0 (en) Vaccine
GB0027433D0 (en) Vaccine component
GB0015935D0 (en) Vaccine
GB0014280D0 (en) Vaccines
GB0006281D0 (en) Vaccines
GB0015736D0 (en) Vaccine
GB0025575D0 (en) Vaccine
GB0005240D0 (en) Vaccine